Interferon Beta for primary progressive multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2010-01-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD006643.pub3PMID 20091602
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interventions for latent autoimmune diabetes (LADA) in adults.

  2011cited by this paper
• Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

  2008cited by this paper
• Primary-progressive multiple sclerosis.

  2007cited by this paper
• Natural history of multiple sclerosis: a unifying concept.

  2006cited by this paper
• The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.

  2006cited by this paper
• Primary progressive multiple sclerosis

  2005cited by this paper
• Placebo-controlled multicentre randomised trial of interferon (cid:1) -1b in treatment of secondary progressive multiple sclerosis

  2005cited by this paper
• Primary Progressive Multiple Sclerosis

  2005cited by this paper
• Overview of London trial of intramuscular interferon-b1a in primary-progressive multiple sclerosis

  2004cited by this paper
• Pure motor stroke with major involvement of the index finger

  2004cited by this paper
• Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

  2004cited by this paper
• Interferon beta-1b in secondary progressive MS

  2004cited by this paper
• Overview of European pilot study of interferon b-1b in primary progressive multiple sclerosis

  2004cited by this paper
• Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

  2003cited by this paper
• Interferon β-1a in primary progressive MS

  2003cited by this paper
• Interferon beta-1a in primary progressive multiple sclerosis.

  2003cited by this paper
• Benefit of interferon &bgr;-1a on MSFC progression in secondary progressive MS

  2002cited by this paper
• The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.

  2001cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  2001cited by this paper
• Diagnostic criteria for primary progressive multiple sclerosis: A position paper

  2000cited by this paper
• Primary and transitional progressive MS

  1999cited by this paper
• Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.

  1999cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cited by this paper
• Primary progressive multiple sclerosis.

  1997cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Consensus definitions of subgroups of multiple sclerosis

  1997cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Defining the clinical course of multiple sclerosis

  1996cited by this paper
• 3 The Cochrane Library

  1996cited by this paper
• A health-related quality of life measure for multiple sclerosis

  1995cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the development of autoimmunity?

  1986cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper

• Quality of the systematic reviews in cochrane multiple sclerosis related articles

  2024cites this paper
• The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran

  2024cites this paper
• Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning

  2022cites this paper
• suppleNext-generation version of recombinant human interferon-beta: A molecular dynamic simulation study

  2022cites this paper
• Motor Behavioral Deficits in the Cuprizone Model: Validity of the Rotarod Test Paradigm

  2022cites this paper
• Pharmakologische Behandlung der multiplen Sklerose

  2020cites this paper
• Sit less and move more: perspectives of adults with multiple sclerosis

  2019cites this paper
• Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis

  2019cites this paper
• Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial

  2019cites this paper
• Palliative care interventions for people with multiple sclerosis.

  2018cites this paper
• Producing an evidence‐based treatment information website in partnership with people affected by multiple sclerosis

  2018cites this paper
• Emerging drugs for primary progressive multiple sclerosis

  2018cites this paper
• In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis

  2018cites this paper
• Interferon Beta: From Molecular Level to Therapeutic Effects.

  2016cites this paper
• Multiple Sclerosis

  2016cites this paper
• Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

  2015cites this paper
• Sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases

  2015cites this paper
• Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis

  2015cites this paper
• Clinical Study The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis : A Double-Blind , Randomized , Placebo-Controlled Trial

  2015cites this paper
• Targeting Inflammatory T Cells in Multiple Sclerosis: Current Therapies and Future Challenges

  2015cites this paper
• Protocolo terapéutico de las formas progresivas primarias y secundarias de la esclerosis múltiple

  2015cites this paper
• Cell therapy for multiple sclerosis: a new hope

  2014influential citation
• Mittel zur Behandlung der multiplen Sklerose

  2014cites this paper
• Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial

  2014cites this paper
• Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

  2014cites this paper
• Therapeutic strategies for relapsing–remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy

  2014cites this paper
• New and emerging immune‐targeted drugs for the treatment of multiple sclerosis

  2014cites this paper
• Current and future therapies targeting the immune system in multiple sclerosis.

  2014cites this paper
• Disease-modifying agents in multiple sclerosis.

  2014cites this paper
• How much detail is needed in cost estimation in an economic evaluation alongside a clinical trial to optimise evidence for decisions

  2014cites this paper
• Imunomodulação da encefalomielite autoimune experimental pelo extrato da glândula salivar de Aedes aegypti.

  2014cites this paper
• Future Therapies for Progressive Multiple Sclerosis

  2013cites this paper
• Primary progressive multiple sclerosis: progress and challenges

  2013cites this paper
• The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial

  2013influential citation
• Immunotherapy of Multiple Sclerosis

  2013cites this paper
• Guideline for the diagnosis and management of multiple sclerosis: a Southern African perspective.

  2013cites this paper
• The American Academy of Neurology's Top Five Choosing Wisely recommendations

  2013cites this paper
• The American Academy of Neurology's Top Five Choosing Wisely recommendations

  2013cites this paper
• Disease-modifying therapies for nonrelapsing multiple sclerosis: Absence of evidence does not constitute evidence of absence.

  2013cites this paper
• Consensus Statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases.

  2013cites this paper
• Consensus Statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases.

  2013cites this paper
• Mechanisms of disease progression

  2013cites this paper
• Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

  2013cites this paper
• Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.

  2013cites this paper
• The first 10 years with multiple sclerosis: the longitudinal course of daily functioning.

  2013cites this paper
• Possible pathomechanisms responsible for injury to the central nervous system in the settings of chronic cerebrospinal venous insufficiency.

  2012cites this paper
• Differential effects of interferon-ß1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients

  2012cites this paper
• Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial

  2012cites this paper
• Pharmacotherapeuetic Options for the Treatment of Multiple Sclerosis

  2012cites this paper
• Targeting Progressive Neuroaxonal Injury

  2011cites this paper
• Immunomodulatory medicines for multiple sclerosis: Progress and prospects

  2011cites this paper
• THE ROLE OF NURSE IN MEDICAL CARE OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS; Update on the Treatment Options for Multiple Sclerosis

  2011influential citation
• Managing MS in a changing treatment landscape

  2011cites this paper
• Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics

  2010cites this paper
• Improving the translational hit of experimental treatments in multiple sclerosis

  2010cites this paper
• Exploring the molecular basis to the regulatory effects of Cannabinoids on toll-like receptor signalling

  2010cites this paper
• Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis.

  2010cites this paper
• Multiple Sclerosis: Autoimmune Disease or Autoimmune Reaction?

  2010cites this paper
• Five-year retrospective study of inpatient occupational therapy outcomes for patients with multiple sclerosis.

  2010cites this paper
• Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?

  2009cites this paper